Immunoglobulin Superfamily, Member 11 (IGSF11) (Middle Region) Peptid
IGSF11
Reaktivität: Human
Wirt: Synthetic
BP, WB
Produktnummer ABIN978452
Kurzübersicht für Immunoglobulin Superfamily, Member 11 (IGSF11) (Middle Region) Peptid (ABIN978452)
Target
IGSF11
(Immunoglobulin Superfamily, Member 11 (IGSF11))
Spezies
Human
Quelle
Synthetic
Applikation
Blocking Peptide (BP), Western Blotting (WB)
-
-
Protein Region
- Middle Region
-
Produktmerkmale
- This is a synthetic peptide designed for use in combination with anti-IGSF11 antibody (Catalog #: ARP44704_P050). It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications.
-
Aufreinigung
- Purified
-
-
-
-
Applikationshinweise
- Each Investigator should determine their own optimal working dilution for specific applications.
-
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Format
- Lyophilized
-
Rekonstitution
- Add 100 μL of sterile PBS. Final peptide concentration is 1 mg/mL in PBS.
-
Konzentration
- 1 mg/mL
-
Buffer
- Final peptide concentration is 1 mg/mL in PBS.
-
Handhabung
- Avoid repeated freeze-thaw cycles.
-
Lagerung
- -20 °C
-
Informationen zur Lagerung
- For longer periods of storage, store at -20°C. Avoid repeat freeze-thaw cycles.
-
-
- IGSF11 (Immunoglobulin Superfamily, Member 11 (IGSF11))
-
Hintergrund
-
IGSF11 functions as a cell adhesion molecule through homophilic interaction. IGSF11 stimulates cell growth.IGSF11 is an immunoglobulin (Ig) superfamily member that is preferentially expressed in brain and testis. It shares significant homology with coxsackievirus and adenovirus receptor (CXADR, MIM 602621) and endothelial cell-selective adhesion molecule (ESAM).[supplied by OMIM].
Alias Symbols: BT-IgSF, CXADRL1, Igsf13, MGC35227, VSIG3, CT119
Protein Size: 431 -
Molekulargewicht
- 46 kDa
-
Gen-ID
- 152404
-
NCBI Accession
- NM_001015887, NP_001015887
-
UniProt
- Q5DX21
Target
-
Sie sind hier:
